Lymphoblast biology and outcome among children with Down syndrome and ALL treated on CCG-1952

Pediatric Blood & Cancer
Mylène BassalLinda C Stork

Abstract

Patients with Down syndrome (DS) and standard risk (SR) acute lymphoblastic leukemia (ALL-DS) are reported to have inferior event free (EFS) and overall survival (OS) compared to patients without DS (ALL-NDS). We compared the prevalence of favorable and unfavorable clinical and biologic features, toxicity and outcome within the ALL-DS and ALL-NDS cohorts of 2,174 eligible patients with SR-ALL enrolled on CCG-1952. Fifty-nine patients (3%) had ALL-DS. DS patients were less likely to have either favorable (hyperdiploidy, triple trisomy of chromosomes 4, 10, and 17, TEL-AML1 rearrangement) or unfavorable (T-cell ALL, hypodiploidy, adverse translocations) biologic features. Toxicity occurred significantly more often and number of days hospitalized was significantly greater in ALL-DS than in ALL-NDS. ALL-DS patients had an inferior 4-year EFS compared to the NDS cohort. However, EFS was equivalent when the comparison excluded ALL-NDS with favorable biologic features. OS was significantly inferior for ALL-DS. The absence of favorable biologic features within ALL-DS contributes to the difference in EFS previously observed between DS and NDS SR-ALL cohorts.

References

Jan 1, 1977·British Journal of Haematology·J Palek
Jun 1, 1992·Leukemia Research·A Aventin
Feb 1, 1990·Archives of Disease in Childhood·G A LevittJ M Chessells
Jul 1, 1987·European Journal of Pediatrics·M Peeters, A Poon
Jan 1, 1988·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H PuiW M Crist
Sep 1, 1968·Archives of Environmental Health·A Milunsky, P W Neurath
Nov 1, 1973·Psychological Medicine·D E JeremiahR W Elliott
Jul 1, 1993·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·C H PuiW M Crist
Jan 1, 1996·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·M SmithR Ungerleider
Mar 21, 1998·Diabetic Medicine : a Journal of the British Diabetic Association·A J AnwarB M Frier
Apr 6, 2000·The New England Journal of Medicine·M AricòG Masera
Apr 3, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P S GaynonH N Sather
Sep 25, 2001·Archives of Disease in Childhood·J M ChessellsI M Hann
Sep 1, 1957·A.M.A. Journal of Diseases of Children·W KRIVIT, R A GOOD
Mar 11, 2004·Blood Reviews·Krzysztof MrózekClara D Bloomfield

❮ Previous
Next ❯

Citations

Nov 10, 2012·Leukemia·C BohnstedtUNKNOWN Nordic Society of Pediatric Hematology and Oncology (NOPHO)
Jan 7, 2009·Journal of Pediatric Hematology/oncology·Catherine BohnstedtKjeld Schmiegelow
Jan 30, 2009·The Oncologist·Karen R Rabin, James A Whitlock
Dec 2, 2014·Pediatric Clinics of North America·Kelly W MaloneyParesh Vyas
Oct 26, 2014·Irish Journal of Medical Science·C O'RaffertyO Smith
Jul 16, 2005·Pediatric Hematology and Oncology·Manuel SteinerUNKNOWN Austrian Berlin-Frankfurt-Münster Group
Nov 19, 2010·Expert Review of Hematology·Ana C XavierJeffrey Taub
Feb 2, 2010·Hematology/oncology Clinics of North America·Rob Pieters, William L Carroll
Feb 2, 2010·Hematology/oncology Clinics of North America·C Michel ZwaanParesh Vyas
Feb 5, 2008·Pediatric Clinics of North America·Rob Pieters, William L Carroll
Feb 5, 2008·Pediatric Clinics of North America·Michel C ZwaanParesh Vyas
May 29, 2008·Pediatric Blood & Cancer·William L Carroll, Elizabeth A Raetz
Oct 24, 2006·British Journal of Haematology·James A Whitlock
Sep 22, 2011·British Journal of Haematology·Kelly W Maloney
Apr 19, 2013·British Journal of Haematology·Franziska MeyrJohann Hitzler
Jan 17, 2014·British Journal of Haematology·Katharine PatrickAjay Vora
Nov 20, 2013·Pediatric Blood & Cancer·Alix E SeifRichard Aplenc
Aug 1, 2006·Cancer Genetics and Cytogenetics·Jennifer J D MorrissetteJ P de Chadarévian
Dec 30, 2014·Pediatric Blood & Cancer·Caroline RoncadinBrenda J Spiegler
Nov 16, 2013·Blood·Shai IzraeliJames Whitlock
Mar 4, 2021·JCO Clinical Cancer Informatics·Nicole M WoodMark A Hoffman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.